ADAMTS12 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 12)

This hybrid feature selection framework applied to patient derived cell lines, effectively reduces dimensionality, enhances biomarker reliability, and uncovers biologically interpretable mRNA signatures associated with ovarian cancer, demonstrating potential for diagnostic and therapeutic applications.

Experimental validation confirmed the significant overexpression of KCNJ15, FASN, and ADAMTS12 in BC tissues. The prognostic model established in this study provides a novel tool for risk stratification of BC patients while simultaneously establishing the foundation for in-depth exploration of PANoptosis mechanisms in BC.

Both targeting circADAMTS12 and PD-L1 blockade effectively suppressed metastatic brain colonization in T cell deficient nude mice, while targeting circADAMTS12 synergized with PD-L1 blockade to block brain metastasis in immunocompetent wild-type mice. These findings suggest that circADAMTS12 suppresses microglial-mediated anti-tumor immunity to support metastatic colonization of breast cancer cells in the brain.

GALNT6 associated with O-GlcNAcylation is overexpressed in OSCC and its knockdown inhibits the growth of OSCC in vitro.

Notably, inhibition of COL3A1 reversed the enhanced cell growth and invasion associated with ADAMTS12 overexpression and suppressed cell apoptosis. Our findings suggest that ADAMTS12 promotes BCa progression through the FAK/PI3K/AKT signaling pathway by regulating COL3A1, highlighting its potential as a valuable marker for diagnosis and prognosis in BCa.

Assessing ADAMTS gene methylation could become a diagnostic tool for differentiating NSCLC subtypes and potentially guide therapeutic strategies. Further research is needed to fully understand the activity and mechanisms of ADAMTS family proteins.

Functional assays further demonstrated that ADAMTS12 promotes GC cell proliferation and invasion. In summary, this study provides critical insights into the molecular landscape of GC, offering a potential prognostic tool and therapeutic target.

Moreover, inflammatory phenotype is exacerbated in the lung after LPS treatment as can be inferred from the accumulation of active immune cells in lung parenchyma. Overall, our results suggest that protective effects in cancer or inflammation shown by fibulin2 and ADAMTS12 as interactive partners in vitro are also shown in a more realistic in vivo context.

Furthermore, the higher ADAMTS9 expression was linked to prolonged survival, while the overexpression of ADAMTS12 was correlated with a shorter survival. These findings suggest that circRNA molecules may serve as potential diagnostic or prognostic biomarkers for NSCLC, highlighting the importance of considering molecular patterns in distinct cancer subtypes.

Metformin can repress the proliferation and glycolysis of GC cells via ADAMTS12. The results suggest the potential of ADAMTS12 being a target for the metformin therapy of GC.

These phenotypic changes, together with the down-regulation of PAI-1, were offset by TGF-β treatment. The present study thus identifies ADAMTS12 as a modulator of HSC differentiation, and a new player in chronic liver disease.